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Abstract 
BACKGROUND AND AIM: Oral lichen planus (OLP) is a chronic, autoimmune, inflammatory disease. The progression of 
OLP to oral squamous cell carcinoma (OSCC) has generated a longstanding controversy about the details of this 
malignant transformation potential. This study aimed to do a systematic review on the molecular markers related to the 
malignant transformation of OLP. 
METHODS: We searched the databases PubMed, Google Scholar, Science Direct, Scopus, Cochrane and Thomson Reuters 
Web of Science (1990-2015) with the MeSH key words of: (“oral lichenoid reaction”, “oral lichenoid lesion”, “oral 
lichenoid eruption”, “oral lichen planus” “lichen planus”, “lichenoid”) AND (“malignant transformation”, “premalignant 
character”, “cancerization”, “pre-neoplasm”, “squamous cell carcinoma”). The reviewers screened the identified 
publications in three steps according to title, abstract and full text, extracted all the investigated markers in screened articles 
and finally classified the markers according to the frequency. Extracted data were saved in Excel software. 
RESULTS: Out of 570 articles, 66 were finally enrolled in the study. The most frequent evaluated markers were p53, 
cyclooxygenase-2 (COX-2), Ki67, B-cell lymphoma-2 (Bcl-2), Bax, p21, and caspase-3. 
CONCLUSION: The present study concluded that there were some documented evidences for association between 
malignant transformation of OLP and seven molecular markers (p53, COX-2, Ki67, Bcl-2, Bax, p21, and caspase-3). 
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ral lichen planus (OLP) is an 
autoimmune muco-cutaneous 
chronic disease that commonly 
involves the oral cavity. The 
prevalence of OLP varies from 0.5% to 3.0%. 
It mainly occurs among females between the 
ages 30 and 60. OLP is classified as white 
(reticular or plaque) and red (atrophic or 
erosive) lesions.1-6 Malignant transformation 
of OLP has been reported,7 and its frequency 
ranges from 0% to 5.3%. The highest 
malignant transformation frequency rate 
occurs in erythematous and erosive lesions.7,8 
The World Health Organization (WHO) has 
categorized this lesion as precancerous, 
which is “a generalized state associated with 
a significant increased risk of cancer”.7 The 
transformation of OLP into oral squamous 
cell carcinoma (OSCC) has led to a 
longstanding controversy about its malignant 
potential.8  
Fitzpatrick et al. conducted a systematic 
review in 2014.9 They evaluated 16 studies on 
the malignant transformation of OLP and 
they focused on its prevalence in clinical 
evidence. The rate of malignant 
transformation ranged between 0% and 3.5%. 
The authors concluded that while there is 
little possibility of malignant degeneration in 
OLP, regular follow-up is necessary for OLP 
patients.9 Molecular markers provide the 
possibility of identifying patients with 
O 
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potential malignancy that are progressing 
toward OSCC before histological detectability 
of malignant cells at the primary region. 
Previous studies have found various types of 
molecular pathways that are possibly 
involved in the transformation of OLP into 
OSCC, such as p53, CDKN1A, LCK, PIK3CA, 
BIRC5, IL-2, and PI3K.8 
 Nowadays, there are no specific markers 
to recognize which OLP lesions have a higher 
risk for malignant transformation. Every 
patient with OLP should be observed  
ultra-carefully to detect early findings for 
cancer development; thus, it is critical to 
identify the main molecular markers such as 
those mentioned. Since Fitzpatrick et al.9 only 
evaluated the clinical characteristics of the 
malignant alteration of OLP, this study aimed 
to identify the specific molecular markers 
related to the malignant transformation of OLP. 
Methods 
In the present study we systematically 
reviewed all the published papers in English 
since January 1990 to December 2015. 
Toward this end, the international electronic 
databases including PubMed, Google 
Scholar, Science Direct, Scopus, Cochrane, 
and ISI Web of Science were searched. Our 
search included (MeSH) the medical 
keywords “oral lichenoid reaction”, “oral 
lichenoid lesion”, “oral lichenoid eruption”, 
“oral lichen planus”, “lichen planus”, and 
“lichenoid” in combination with “malignant 
transformation”, “premalignant character”, 
“cancerization”, “pre-neoplasm”, and 
“squamous cell carcinoma”. In the next step, 
to identify other related articles we 
considered summaries of all presentations at 
international congresses in the field of oral 
health during the specified period  
(1990–2015). In addition, we used the 
references cited in the related papers in order 
to prevent us from missing any pertinent 
data or studies. All the obtained articles were 
imported into EndNote software. The 
software eliminated duplicate studies. The 
investigator screened the relevant 
publications in three steps based on the titles, 
abstracts, and body text. The investigator also 
screened the articles according to the strength 
of their methods.10,11  
Therefore, case-reports or studies without 
any comparison with a control group or 
without a reliable diagnostic test were 
excluded. The included papers were case-
control studies with both human and biopsy 
samples. We extracted data in two phases. 
First, we evaluated the overall related 
qualified studies and we extracted all the 
investigated molecular markers. In the 
second data extraction phase, we 
categorized the molecular markers 
according to their frequency. The obtained 
data included papers that examined special 
molecular markers. The collected papers 
were classified based on the number of 
repeated markers they contained: repeated 
more than once and repeated once. The data 
were extracted and then saved separately in 
an Excel worksheet. 
Results 
First, 570 articles were collected from the 
previously mentioned databases (Cochrane: 
8, PubMed: 347, Google Scholar: 141, Science 
Direct: 41, Scopus: 27, Web of Science: 6). 
after removing duplicate articles, the 
remaining records were evaluated based on 
their title and abstract. Finally, 66 records 
were selected (Figure 1). Reviewing the full 
texts of those 66 articles enabled us to clarify 
the most important molecular markers in 
these studies. The extracted and stratified 
data [regarding the author, year, study 
group(s), technique, and detection of markers 
in the OLP group] for these reviewed articles 
are shown in tables 1-3. 
 
 
Figure 1. Flow diagram of study 
570 articles identified 
through database searching 
306 duplicate 
articles removed 
101 articles removed 
based on title and 
abstract 
97 articles failed to 
meet the inclusion 
criteria 
the remaining 66 articles 
systemically reviewed 
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Table 1. Description of the reviewed studies for the main seven markers 
Studies/ 
Marker 
Author Year Study group(s) Technique 
Detection 
of marker 
in OLP 
Twelve 
studies for 
p53 
Acay et al.
13 
2006 22 OLP, 27 OLL IHC + 
Agha-Hosseini and 
Mirzaii-Dizgah
14 2015 35 OLP, 38 NM ELISA NC 
Arreaza et al.
15 
2013 31 OLP, 34 OLR IHC + 
de Sousa et al.
29 
2009 24 OLP, 24 OSCC IHC + 
Gonzalez-Moles et al.
33 
2006 51 OLP, 26 NM IHC + 
Lee et al.
38 
2004 
56 OLP, 20 NM, 20 EH, 30 ED, 
38 SCC 
IHC NC 
Leyva-Huerta et al.
39 
2012 21 OLP, 16 OSCC, 4 NM IHC + 
Ogmundsdottir et al.
55 
2002 55 OSCC, 48 OLP, 12 NM IHC NC 
Oliveira Alves et al.
56 
2013 
5NM, 25 IFH, 65 OLP, 16 OED, 
19 OSCC 
IHC + 
Safadi et al.
65 
2010 
18 OLP, 10 NM, 10 OSCC, 13 
NM, 20 OFK, 30 OED 
IHC - 
de Sousa et al.
29 
2009 24 OLP, 24 OED IHC + 
Valente et al.
73
 2000 28 OLP, 7 NM IHC NC 
Seven 
studies for 
COX-2 
Abdel Hay et al.
12 
2011 50 OLP, 50 NM RFLP, RT-PCR, RIA - 
Arreaza et al.
16 
2014 34 OLR. 31 OLP IHC + 
Cortes-Ramirez et al.
26 
2010 44 OLP IHC + 
Danielsson et al.
28 
2011 20 OLP, 20 NM 
RT-PCR, IHC, 
Western blot 
+ 
Li et al.
40 
2013 33 OLP, 38 OSCC, 10 NM IHC, RT-PCR + 
Lysitsa et al.
42 
2007 30 OLP, 8 NM Western blot + 
Neppelberg and 
Johannessen
53 2007 7 NM, 45 OLP IHC - 
Seven 
studies for 
Bcl-2 
Arreaza et al.
16 
2014 34 OLR, 31 OLP IHC + 
de Sousa et al
29 
2009 24 OLP, 24 OSCC IHC - 
Gonzalez-Moles et al.
33 
2006 51 OLP, 26 NM IHC + 
Leyva-Huerta et al.
39 
2012 21 OLP, 16 OSCC, 4 NM IHC + 
Nafarzadeh et al.
51,52 
2013 11 WOSCC, 30 OLP, 20 NM IHC ? 
Pigatti et al.
57 
2014 14OLP, 14 OLL , 9 NM IHC + 
Sousa et al.
69
 2009 24 OLP, 24 OED IHC + 
Six studies 
for Ki67 
Acay et al.
13 
2006 22 OLP, 27 OLL IHC - 
Gonzalez Moles et al.
32 
2009 Ninety OSCCs from 73 patients IHC + 
Gonzalez-Moles et al.
33 
2006 51 OLP, 26 NM IHC NC 
Mattila et al.
46 
2007 70 OLP IHC - 
Pigatti et al.
57 
2014 14 OLP, 14 OLL, 9 NM IHC ?+ 
Zargaran et al.
75 
2013 
17 EH, 16 OLP, 10 MED, 10 
SED, 10 WOSCC,10 POSCC 
IHC + 
Five studies 
for Bax 
Bascones et al.
17 
2005 32 OLP, 20 NM TUNEL assay, IHC - 
Bascones-Ilundain et 
al.
18 2007 
32 OLP (18 reticular and 14 
atrophic-erosive) 
IHC NC 
de Sousa et al.
29 
2009 24 OLP, 24 OSCC IHC - 
Nafarzadeh et al.
51,52 
2013 11 WOSCC, 30 OLP, 20 NM IHC + 
Sousa et al.
69 
2009 24 OLP, 24 OED IHC + 
Four 
studies for 
p21 
Bascones et al.
17 
2005 32 OLP, 20 NM TUNEL assay, IHC + 
Bascones-Ilundain et al.
19 
2006 32 OLP, 20 NM IHC, TUNEL assay + 
Gonzalez-Moles et al.
33 
2006 51 OLP, 26 NM IHC + 
Safadi et al.
65 
2010 
18 OLP, 10 NM, 10 OSCC, 13 
OM, 20 OFK, 30 OED 
IHC + 
Four 
studies for 
Caspase-3 
Bascones et al.
17 
2005 32 OLP, 20 NM TUNEL assay, IHC + 
Bascones-Ilundain et 
al.
18 2007 
32 OLP (18reticular and 14 
atrophic-erosive) 
IHC - 
Bascones-Ilundain et al.
19 
2006 32 OLP, 20 NM IHC, TUNEL assay + 
Gonzalez-Moles et al.
33 
2006 51 OLP, 26 NM IHC + 
OLP: Oral lichen planus; OLL: Oral leukoplakia; OLR: Oral lichenoid reaction; NM: Normal mucosa; OSCC: Oral squamous cell 
carcinoma; EH: Epithelial hyperplasia; OED: Oral epithelial dysplasia; MED and SED: Mild; Moderate and severe epithelial 
dysplasia; OFK: Oral focal keratosis; WOSCC and POSCC: Well-differentiated and poorly-differentiated OSCC; NC: Non-
conclusive; OM: Oral mucositis; IHC: Immunohistochemistry; ELISA: Enzyme-linked immunosorbent assay; RFLP: Restriction 
fragment length polymorphism; RT-PCR: Reverse transcription polymerase chain reaction; RIA: Radioimmunoassay; TUNEL assay: 
Terminal deoxynucleotidyl transferase dUTP nick-end labeling assay 
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Table 2. Markers repeated in two studies 
Marker 
Author Year Study group(s) Technique 
Detection of 
marker in OLP 
PCNA Lee et al.
38 
2004 56 OLP, 20 NM, 20 EH, 30 ED, 38 SCC IHC ? 
Sousa et al.
69 
2009 24 OLP, 24 dysplasia IHC + 
MMPs Chen et al.
22 
2008 27 OLP, 15 OSCC, 11 NM
*
 IHC + 
Li et al.
40 
2013 33 OLP, 38 OSCC, 10 NM IHC, RT-PCR + 
E-
cadherin 
Mattila et al.
47
 2008 70 OLP IHC, static 
DNA cytometry 
- 
Neppelberg and 
Johannessen
53 
2007 7 NM, 45 OLP
*
 IHC - 
MMP: Matrix metalloproteinases; PCNA: Proliferating cell nuclear antigen; OLP: Oral lichen planus; NM: Normal mucosa; EH: 
Epithelial hyperplasia; ED: Epithelial dysplasia; SCC: Squamous cell carcinoma; OSCC: Oral squamous cell carcinoma; NM: 
Normal mucosa; IHC: Immunohistochemistry; RT-PCR: Reverse transcription polymerase chain reaction 
 
As shown in those tables, the main result 
of the reviewed studies denotes the 
significant existence of a particular marker in 
OLP. Table 1 shows the collected data for 
seven markers repeated in more than two 
studies: p53, cyclooxygenase-2 (COX-2), Ki67, 
B-cell lymphoma-2 (Bcl-2), Bax, p21, and 
caspase-3.  
 
Table 3. Markers repeated in one study 
Author Year Marker(s) 
Detection of 
marker in OLP 
Rivarola de Gutierrez et al.
63 
2014 CK1 - 
Chen et al.
44 
2008 TIMP-2, TGF-b1 + 
Cheng et al.
23 
2014 DUSP1; H3F3A; OAZ1;S100P; SAT1 + 
Cheng et al.
24
 2011 ET-1 + 
Czerninsk et al.
27 
2013 SCCA + 
Czerninsk et al.
27 
2013 TPS, VEGF - 
Danielsson et al.
28 
2011 miR-26b + 
Gonzalez Moles et al.
29 
2009 SP, NK-1R + 
Hakkinen et al.
36 
1999 Integrin a9 subunit, tenascin + 
Li et al.
40 
2013 CXCL9 - 
Ma et al.
43
 2013 Bmi1 + 
Mattila et al.
46 
2007 CK-19 - 
Mattila et al.
46 
2007 Topoisomerase II + 
Mattila et al.
47 
2008 cdk-1, Rad-51 - 
Mattila et al.
47 
2008 desmocollin-1 + 
Montebugnoli et al.
49
 2011 p16INK4A - 
Nafarzadeh et al.
51,52 
2013 Smad3 + 
Oliveira Alves et al.
56 
2013 SUMO-1 - 
Oliveira Alves et al.
56 
2013 MDM2 + 
Pimenta et al.
58 
2004 hMSH2 + 
Poomsawat et al.
59 
2011 cdk6 - 
Poomsawat et al.
59 
2011 cdk4, p16 + 
Prodromidis et al.
60
 2013 p-Akt, p-mTOR, phospho-pS6 + 
Rhodus et al.
62
 2005 NF-Kb, TNF-a, + 
Rivarola de Gutierrez et al.
63 
2014 CK13, CK14 - 
Segura et al.
66 
2013 MYC status + 
Shi et al.
67 
2010 Podoplanin, ABCG2 + 
Sun et al.
70
 2013 CD133 + 
Thongprasom et al.
72 
1998 Telomerase activity + 
Valente et al.
73
 2000 MIB-1 - 
Xu et al.
74
 2013 ALDH1 + 
Zhang et al.
76 
1997 LOH + 
OLP: Oral lichen planus; OLL: Oral leukoplakia; OLR: Oral lichenoid reaction; NM: Normal mucosa; OSCC: Oral squamous cell 
carcinoma; EH: Epithelial hyperplasia; ED: Epithelial dysplasia; OED: Oral epithelial dysplasia; MED and SED: Mild; moderate and 
severe epithelial dysplasia; OFK: Oral focal keratosis; WOSCC and POSCC: Well-differentiated and Poorly-differentiated OSCC; 
NC: Non-conclusive; OM: Oral Mucositis; IHC: Immunohistochemistry; ELISA: Enzyme-linked immunosorbent assay; RFLP: 
Restriction fragment length polymorphism; RT-PCR: Reverse transcription polymerase chain reaction; RIA: Radioimmunoassay 
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It is important to note that these markers 
were highlighted in 45 studies. The marker 
studied most often was p53 (in 12 studies). 
The markers that were least often studied 
were p21 and caspase-3 (in four studies). The 
markers that were only repeated in two 
studies are listed in table 2. The markers that 
were only repeated in one study are 
presented in table 3. 
Discussion 
This review focused on the most frequent 
molecular markers of OLP malignancy, 
which were examined in 66 articles, and 
reported on the frequency of these markers. 
Based on those 66 studies, there were seven 
principal markers for malignant 
transformation: p53, COX-2, Ki67, Bcl-2, Bax, 
p21, and caspase-3.12-77 
p53 is the maker that is most frequently 
investigated in the studies in this systematic 
review. In the normal development of a cell, 
the p53 protein level is low because it has a 
short half-life; otherwise, in situations in 
which a cell can tolerate additional pressure 
the production of this marker saves the cell 
and it would not prevent apoptosis. The 
wild-type p53 protein has an opposite effect 
on cell proliferation, and it can inhibit the cell 
cycle process between the G1 and S phases. It 
has been shown that the p53 mutation 
increases proliferative activity; the expression 
of this protein is altered in OSCC and in 
potentially malignant oral lesions.13,15,38,39,73 
COX-2 and Bcl-2 (the second most frequent 
markers found in this systematic review) are 
important factors in inflammation and 
carcinogenesis. Overexpression of COX-2 is 
indicated in cancer development, including 
invasion, metastasis, angiogenesis, and other 
cancer-related steps. The increased 
expression of COX-2 has been reported in 
pre-cancerous lesions, including squamous 
cell carcinoma and OLP.12,26,28,40,42 
The Bcl-2 protein is responsible for 
translocation in follicular lymphoma. Bcl-2 
could protect cells against apoptosis. Bcl-2 is 
located in the inner mitochondrial 
membrane, and to a lesser extent in the 
nuclear membrane and the endoplasmic 
reticulum. Bcl-2 activity correlates with p53 
because its expression prevents apoptosis. 
Cell proliferation and apoptosis are altered in 
the carcinogenesis process. Bcl-2 and Bax 
have an important role in this alteration. 
Therefore, any altered expression and 
function of Bcl-2 and Bax could be an 
indicator of malignant transformation in a 
lesion. This mechanism has been described 
for oral cancer.30,34,39,52 in the present study, 
the expression of Ki67 was ranked fourth in 
terms of its effect on the creation of 
precancerous and cancerous oral lesions. It 
has been described that Ki67 has an effect on 
the active phases of a cell cycle (G1, S, G2). Its 
expression rate depends on cellular 
proliferation. It might be promising as a first 
index of malignancy.13,46 p21 tumor 
suppressor genes produce the p53 protein. 
p21 induces suppressive outcome on the 
function of cyclin-dependent kinase. This 
enzyme plays a controlling role in G1 to S 
phase (cell cycle). It has been shown that p21 
overexpresses in oral epithelial dysplastic 
lesions and OSCC. Therefore, this gene 
expression could be used to identify the 
prognosis of oral malignancy.65 Apoptosis is 
a defensive factor. It might protect cells from 
malignant transformation. The process of 
apoptosis depends on many molecular 
effecters. Caspase-3 is involved in 
proteolysis, and this special factor leads to 
the activation of apoptosis.17 
In almost all the reviewed studies, the case 
group consisted of a number of cases with the 
diagnosis of lichen planus, unlike the control 
groups that showed a remarkable diversity of 
diseases, including oral leukoplakia, OSCC, 
oral epithelial dysplasia, and epithelial 
hyperplasia as well as normal mucosa. The 
wide clinical and histological spectra of these 
entities in the control groups are significant. 
Safadi et al.65, Zargaran et al.75 and Lee et al.38 
divided their studied patients into five groups. 
Nevertheless, it seems that comparing more 
than two groups in one study causes 
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complexity in the data interpretation. 
Significantly, studies, such as those conducted 
by Bascones-Ilundain et al., have examined the 
high-risk clinical view of lichen planus 
(atrophic-erosive) for malignancy.17-19  
In the present study, review of the  
66 articles also found a notable diversity in the 
sample sizes, ranging from 14 to 70 cases for 
OLP in the examined studies. It seems that 
using the average number from that range 
(almost 40 cases of lichen planus) is reliable. 
As shown in tables 1 and 2, the reviewed 
articles used eight different diagnostic 
methods to determine the presence of the 
molecular markers mentioned in their 
samples. These eight methods included 
immunohistochemistry (IHC), Enzyme-
linked immunosorbent assay (ELISA), 
Restriction fragment length polymorphism 
(RFLP), Reverse-transcription polymerase 
chain reaction (RT-PCR), double-antibody 
radioimmunoassay (RIA), Western blot, the 
Terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL) assay, and static 
DNA cytometry. IHC was the primarily used 
method (45 out of 66 studies). The influence 
that using a specific test had on the result of 
the studies is unclear. Abdel Hay et al.12 were 
the only researchers who used RFLP and 
RIA, and Agha-Hosseini and Mirzaii-Dizgah 
exclusively utilized ELISA in their study.14 
Some researchers, such as Danielsson et al.28 
and Abdel et al.12 used three different 
techniques in one study; however, the 
advantage of this approach is unclear. 
Giacomelli et al.8 studied the relationship 
between OLP and OSCC in a new way using 
the leader genes approach. In this method, 
the data search for genes involved a specific 
process done systematically. Then, the data 
are ranked based on the number of 
interconnections with the other identified 
genes. This suggests that some key genes and 
encoded proteins are possibly involved in the 
malignant potential of OLP;8 hence, that 
study has a good agreement with the 
findings of this study. 
One of the limitations of this study was that 
the collected data could not be pooled due to 
different methods that were used and the study 
groups that were examined; thus, there was not 
a possibility to carry on a meta-analysis. 
Conclusion 
The present study concluded that several 
molecular alterations, including p53, COX-2, 
Ki67, Bcl-2, Bax, p21, and caspase-3, which 
are involved in pre-neoplastic alterations, are 
measurable in OLP. It seems that three 
factors have serious implications for the lack 
of agreement in this field of research: 1) using 
different diagnostic tests, 2) choosing different 
numbers for the sample sizes, and 3) 
considering miscellaneous features for the 
case and control groups. To identify a definite 
relationship, we suggest further studies on 
both the most possible and the uncertain 
groups of molecular markers in this field. 
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